Press release
Hypoglycemia Market Poised for Notable Growth by 2032, Fueled by Innovation and FDA Breakthrough for Rezolute's Ersodetug | Eiger BioPharmaceuticals, MBX Biosciences, Hanmi Pharmaceutical, and others.
Hypoglycemia Market
DelveInsight's latest 7MM report, "Hypoglycemia Market Report [https://www.delveinsight.com/report-store/hypoglycemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]," provides a comprehensive analysis of market trends, epidemiological insights, and emerging therapies. The report covers detailed forecasts and unmet needs across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, offering strategic guidance to stakeholders.
Some of the key facts of the Hypoglycemia Market Report:
- The total hypoglycemia market size is estimated to grow with a significant CAGR during the study period (2019-2032).
- Approximately 57.44% of diabetes patients experience hypoglycemia, with nearly 11% encountering severe episodes.
- The age-standardized proportion of hypoglycemia-related deaths is 4.49 per 1,000 total diabetes deaths across 109 countries.
- In the United States, severe hypoglycemia is associated with a 3.4-fold increase in 5-year mortality among diabetes patients.
- In the U.S., approximately 2-5% of hospitalized patients with diabetes mellitus experience severe hypoglycemia.
- In May 2025, Rezolute, Inc. (Nasdaq: RZLT) announced that the FDA granted Breakthrough Therapy Designation to its investigational drug, Ersodetug, for treating hypoglycemia caused by tumor-induced hyperinsulinism (HI).
- In March 2025, Xeris Biopharma Holdings, Inc. announced that its supplemental new drug application (sNDA) for Gvoke VialDx Trademark received FDA approval for use as a diagnostic aid during radiologic exams to temporarily inhibit gastrointestinal tract movement in adult patients.
- In September 2024, Rezolute, Inc. announced that the FDA has lifted the partial clinical holds on RZ358 (ersodetug), its novel therapy for treating hypoglycemia in patients with congenital hyperinsulinism (HI). This marks a significant step forward in developing this potential treatment for the rare disease.
- Leading hypoglycemia therapies include Avexitide, MBX 1416, HM 15136, TB 222 023, and others.
- Leading companies in the hypoglycemia market include Eiger BioPharmaceuticals, MBX Biosciences, Hanmi Pharmaceutical, Twist Bioscience, and others.
To know in detail about the hypoglycemia market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Hypoglycemia Market Forecast [https://www.delveinsight.com/report-store/hypoglycemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Hypoglycemia Overview
Hypoglycemia, commonly known as low blood sugar, is a condition where the glucose levels in the bloodstream drop below normal, typically below 70 mg/dL. It is most commonly associated with diabetes, particularly in patients who are on insulin or other medications that increase insulin production. However, hypoglycemia can also occur in people without diabetes due to factors such as prolonged fasting, excessive alcohol consumption, or certain medical conditions.
The symptoms of hypoglycemia include shaking, sweating, confusion, dizziness, weakness, and in severe cases, loss of consciousness, seizures, and even death. If left untreated, severe hypoglycemia can be life-threatening. The condition is typically managed by consuming fast-acting carbohydrates, such as glucose tablets or sugary drinks, to raise blood sugar levels quickly.
Hypoglycemia is a significant concern for individuals with diabetes as it can lead to dangerous fluctuations in blood sugar, increasing the risk of both short-term and long-term complications. As a result, effective monitoring, personalized treatment plans, and ongoing management are critical to minimize the risk of hypoglycemia in diabetic patients. Research into treatments and therapies for hypoglycemia is ongoing, with promising developments aimed at improving patient outcomes.
Get a free sample for the hypoglycemia market report:https://www.delveinsight.com/report-store/hypoglycemia-market [https://www.delveinsight.com/report-store/hypoglycemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Hypoglycemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hypoglycemia Epidemiology Segmentation:
The hypoglycemia epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
- Type-specific Bariatric Surgery Cases
- Total Postbariatric Hypoglycemia (PBH) Cases
- Postbariatric Hypoglycemia (PBH) Cases in types of Bariatric Surgeries
- Severity-specific Postbariatric Hypoglycemia (PBH) Cases
- Total Treated Cases of Postbariatric Hypoglycemia (PBH) Cases
Download the report to understand which factors are driving hypoglycemia epidemiology trends at Hypoglycemia Epidemiology Forecast [https://www.delveinsight.com/report-store/hypoglycemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Hypoglycemia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the hypoglycemia market or expected to be launched during the study period. The analysis covers the hypoglycemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the hypoglycemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing, patent details, and other information for emerging therapies.
Hypoglycemia Market Strengths
- The rising number of diabetes cases worldwide increases the demand for hypoglycemia treatments, creating a large market for related therapies.
- Ongoing innovations in hypoglycemia management, including the development of new drugs and technologies, are enhancing treatment options and improving patient outcomes.
Hypoglycemia Market Weaknesses
- The cost of advanced hypoglycemia treatments, particularly for rare causes like tumor hyperinsulinism, can be prohibitive for many patients, limiting market accessibility.
- There is a lack of awareness about hypoglycemia outside of diabetes management, which may hinder the identification of potential patients and slow market growth in non-diabetic hypoglycemia cases.
Scope of the Hypoglycemia Market Report
- Study Period: 2019-2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Hypoglycemia Companies: Eiger BioPharmaceuticals, MBX Biosciences, Hanmi Pharmaceutical, Twist Bioscience, and others.
- Key Hypoglycemia drugs: Avexitide, MBX 1416, HM 15136, TB 222 023, and others.
- Hypoglycemia Therapeutic Assessment: Hypoglycemia currently marketed, and Hypoglycemia emerging therapies
- Hypoglycemia Market Dynamics: Hypoglycemia market drivers and Hypoglycemia market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Hypoglycemia Unmet Needs, KOL's views, Analyst's views, Hypoglycemia Market Access and Reimbursement
To learn more about the key players and advancements in the hypoglycemia treatment landscape, visit the Hypoglycemia Market Analysis Report [https://www.delveinsight.com/report-store/hypoglycemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Table of Contents
1. Hypoglycemia Market Report Introduction
2. Executive Summary for Hypoglycemia
3. SWOT analysis of Hypoglycemia
4. Hypoglycemia Patient Share (%) Overview at a Glance
5. Hypoglycemia Market Overview at a Glance
6. Hypoglycemia Disease Background and Overview
7. Hypoglycemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Hypoglycemia
9. Hypoglycemia Current Treatment and Medical Practices
10. Hypoglycemia Unmet Needs
11. Hypoglycemia Emerging Therapies
12. Hypoglycemia Market Outlook
13. Country-Wise Hypoglycemia Market Analysis (2019-2032)
14. Hypoglycemia Market Access and Reimbursement of Therapies
15. Hypoglycemia Market Drivers
16. Hypoglycemia Market Barriers
17. Hypoglycemia Appendix
18. Hypoglycemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypoglycemia-market-poised-for-notable-growth-by-2032-fueled-by-innovation-and-fda-breakthrough-for-rezolutes-ersodetug-eiger-biopharmaceuticals-mbx-biosciences-hanmi-pharmaceutical-and-others]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypoglycemia Market Poised for Notable Growth by 2032, Fueled by Innovation and FDA Breakthrough for Rezolute's Ersodetug | Eiger BioPharmaceuticals, MBX Biosciences, Hanmi Pharmaceutical, and others. here
News-ID: 4007970 • Views: …
More Releases from ABNewswire
Understanding Magnetic Switches: Types, Working Principles, and Applications
A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications.
What is a Magnetic Switch?
A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed…
Innovating embedded downlight technology: Leading the global trend of intelligen …
The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded…
North China Electric Power University Foreign Aid Training Program Visits Yiyuan …
On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives.
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg
Upon arrival, the delegation received a warm welcome from company leadership and the reception…
Pure Sine Wave Low Frequency Inverter Charger
Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current…
More Releases for Hypoglycemia
Hypoglycemia Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Ke …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hypoglycemia pipeline constitutes 10+ key companies continuously working towards developing 12+ Hypoglycemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Hypoglycemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
Hypoglycemia Market to Reach USD 2.5 Billion by 2034
Hypoglycemia, commonly defined as abnormally low blood glucose levels, is a serious condition that often affects individuals with diabetes receiving insulin or other glucose-lowering therapies. Symptoms range from dizziness, sweating, and confusion to seizures and coma in severe cases. Beyond diabetes, hypoglycemia can also result from metabolic disorders, hormone deficiencies, excessive alcohol intake, or post-surgical complications.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72031
With diabetes incidence rising globally and…
Severe Hypoglycemia Market to Reach USD 3.2 Billion by 2034
Severe hypoglycemia is a critical, potentially life-threatening condition marked by dangerously low blood glucose levels, most often occurring in patients with diabetes mellitus treated with insulin or insulin secretagogues. It can lead to seizures, unconsciousness, and, in extreme cases, death. Beyond the immediate medical risks, recurrent severe hypoglycemia significantly affects quality of life and increases the burden on healthcare systems.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72047
As the…
Postbariatric Hypoglycemia Market Growth, Applications, Innovations and Business …
Introduction
Postbariatric hypoglycemia (PBH) is an increasingly recognized complication of bariatric surgery, especially gastric bypass procedures. Characterized by low blood sugar after eating, PBH is often caused by rapid glucose absorption and exaggerated insulin release. Symptoms range from dizziness, fatigue, and palpitations to severe neuroglycopenic events like confusion, seizures, and unconsciousness.
With the global obesity epidemic driving higher rates of bariatric surgery, PBH cases are becoming more common. Growing awareness among physicians…
Hypoglycemia Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Upda …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hypoglycemia pipeline constitutes 10+ key companies continuously working towards developing 12+ Hypoglycemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Hypoglycemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
Postbariatric Hypoglycemia Treatment Market Size, Drugs, Emerging Therapies and …
Postbariatric Hypoglycemia Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Postbariatric Hypoglycemia Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Postbariatric Hypoglycemia Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Postbariatric Hypoglycemia, historical and…
